Allure Labs Cited for Suspected Underreporting of Problematic OTC Drug Events, Testing Lapses

The FDA issued over-the-counter (OTC) drug and cosmetic manufacturer Allure Labs a four-observation Form 483 following a November to December 2021 inspection of its Hayward, Calif., facility, noting procedural lapses…

Continue ReadingAllure Labs Cited for Suspected Underreporting of Problematic OTC Drug Events, Testing Lapses